Ligand Appoints Dr. Nancy Gray to its Board of Directors
August 21 2017 - 9:00AM
Business Wire
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
(“Ligand” or “the Company”) announces the appointment of Nancy Ryan
Gray, Ph.D. to the Company’s Board of Directors, effective today.
Dr. Gray currently serves as President and Chief Executive Officer
of Gordon Research Conferences, a not-for-profit organization that
arranges conferences in the biological, chemical, and physical
sciences worldwide. Dr. Gray’s appointment increases the number of
Ligand directors to eight.
“Nancy is a dynamic and extremely well-connected executive who
will bolster Ligand’s relationships with the scientific community
and provide a valuable perspective as we advance our Shots-on-Goal
business model,” said John Kozarich, Chairman of Ligand. “We
welcome her to the Ligand board of directors.”
Prior to joining Gordon Research Conferences in 2003, for nine
years Dr. Gray was with the American Chemical Society (ACS) in
Washington, D.C., the world’s largest scientific society, most
recently as Director of Membership. She also was the liaison to the
Board Committee on Grants and Awards and the Council Committee on
Nominations and Elections, and was responsible for the ACS national
election process. Prior to joining the ACS, Nancy spent nine years
as a Senior Research Scientist at Exxon/Mobil Research and
Engineering (formerly Exxon Production Research) in Houston.
Dr. Gray is a Fellow of the Royal Society of Chemistry, a Fellow
of the American Association for the Advancement of Science and a
member of the American Chemical Society.
Dr. Gray received a B.S. in chemistry from the University of
Notre Dame and a Ph.D. in Fuel Chemistry from The Pennsylvania
State University. She was a Research Fellow at the Foundation on
Matter Institute for Atomic and Molecular Physics in Amsterdam, and
completed the Harvard Executive Education Finance for Senior
Executives program. She also has authored or co-authored numerous
scientific articles.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on developing or
acquiring technologies that help pharmaceutical companies discover
and develop medicines. Our business model creates value for
stockholders by providing a diversified portfolio of biotech and
pharmaceutical product revenue streams that are supported by an
efficient and low corporate cost structure. Our goal is to offer
investors an opportunity to participate in the promise of the
biotech industry in a profitable, diversified and lower-risk
business than a typical biotech company. Our business model is
based on doing what we do best: drug discovery, early-stage drug
development, product reformulation and partnering. We partner with
other pharmaceutical companies to leverage what they do best
(late-stage development, regulatory management and
commercialization) to ultimately generate our revenue. Ligand’s
Captisol® platform technology is a patent-protected, chemically
modified cyclodextrin with a structure designed to optimize the
solubility and stability of drugs. OmniAb® is a patent-protected
transgenic animal platform used in the discovery of fully human
mono-and bispecific therapeutic antibodies. Ligand has established
multiple alliances, licenses and other business relationships with
the world’s leading pharmaceutical companies including Novartis,
Amgen, Merck, Pfizer, Celgene, Gilead, Janssen, Baxter
International and Eli Lilly.
Follow Ligand on Twitter @Ligand_LGND.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170821005176/en/
Ligand Pharmaceuticals IncorporatedTodd
Pettingillinvestors@ligand.com(858) 550-7500@Ligand_LGNDorLHABruce
Vossbvoss@lhai.com(310) 691-7100
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Sep 2023 to Sep 2024